AI assistant
Sending…
CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2017
Jan 5, 2017
31542_dirs_2017-01-05_c87dc09f-cd76-4dcc-b0b0-cc2c89df16bd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2017-01-03
Reporting Person: Miller Steve (Chief Operating Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-01-03 | Options to purchase common stock | $1.13 | A | 50000 | Acquired | 2024-01-03 | Common Stock (50000) | Direct |
| 2017-01-03 | Options to purchase common stock | $1.13 | A | 50000 | Acquired | 2024-01-03 | Common Stock (50000) | Direct |
| 2017-01-03 | Options to purchase common stock | $1.13 | A | 50000 | Acquired | 2024-01-03 | Common Stock (50000) | Direct |
More from CATALYST PHARMACEUTICALS, INC.
M&A Activity
2026
Jun 8
Report Publication Announcement
2026
May 11
M&A Activity
2026
May 7
Major Shareholding Notification
2026
Mar 26
Earnings Release
2026
Feb 25
Annual Report
2026
Feb 25
Director's Dealing
2026
Feb 19
Investor Presentation
2026
Jan 12
Director's Dealing
2026
Jan 6
Director's Dealing
2026
Jan 6